Member Info for Saint68

Mac - could be a number of companies but my list would include Citic, Sinosteel or CS’s company.

Keith is definitely still working for the company. Had an email from him earlier this afternoon.

:-)

I've emailed the company about the bonds and the tax rebates. Will update here when / if I get a response.

Yes that's a possibility Del and they've previously taken that option.

The BOD obviously have found a way to get CURRENT spending down and have predicted that they have enough to last until the end of Q1 so I will take them at their word and not your estimate based on previous cash burn.

Del - not being comfortable and seeking to get them removed are 2 different things. What do you think a new BOD would be able to do in the current climate ?

GM - I have let you know - it states end of Q1 2024 - is that 8 weeks from November ?

@Del - "doing feck all" - you have no idea what they're doing in the background so best you reserve judgement.

GM402 - from the RNS "the Company has sufficient working capital to meet ongoing obligations until the end of Q12024." - that's the end of March 2024 so not 8 weeks from November.

@Del - probably because they have clueless pi's continually hassling them with pointless questions asking for info.

Why the fluck would you want to that Del ? Would you rather them start to mine now and run out of money by the end of the month ? Sorry but you're starting to sound more like Toffers by the day. Chill and let this play out. Changing the BOD at this late stage would be of benefit to nobody.

EIE01 - "What is EXTREMELY frustrating is the fact the company is still in active discussions to sell the concentrate, why is it taking so long." - I believe this is linked to the ongoing tax issue that is due to be heard and possibly concluded on December 13th.

1. MT DFS details published. - I think CS stated in the AGM that it couldn't be release until given clearance by the Russia authorities.

3. Who received the VAT credits & how much more we are due (in local currency) - will probably be in the annal report and I don't think and RNS is needed for this

8. What the Logik & QVL/Mispare court cases cost EUA - will be in the annual report (2024) I would imagine

9. Update on the WUP with Gowling WLG (UK) LLP. - both due to be heard on the 13th

Del - I get that you're peeved with CS but you were the same way pre AGM and after it you were a little more upbeat. He stated in the AGM that his hands are tied as to what he can update shareholders about due to NDA's. Nobody on these boards know what the NDA's cover but I'm guessing that if the information could be released it would be. Be careful what you wish for and having someone new in post will not change the fact that the NDA's would still be in place so we'd be none the wiser.

Just going back to my original question, a pharma company is driven by profit. So if less drug is used and no drugs for side effects are needed anymore, what advantage does the pharma company get with Pre | cision? - I'll keep it simple for you Oily. 1 company has pre/cision Dox (the new standard of care). 20 other companies have standard Dox. The standard Dox becomes nigh on obsolete overnight and all their Dox business goes to the 1 company. How much profit do you think that 1 company then stands to make ?

Oil - - !Does the Pre | cision Platform bring more profit to pharma compared to the standalone drug - NO as you will likely need less drug and fewer doses"??

If Pre/cision is as good as we think and it becomes the standard of care overnight, the standalone drugs will become irrelevant. It can applied to many chemotherapies so big pharma will need it or they will see a huge fall in their profits.

Sounds promising :

https://youtube.com/live/g6ePGvdmlmw?si=GETGyT_gK18q24sv

HT - Brain lymphoma, also known as primary cerebral lymphoma or primary central nervous system lymphoma, is a rare, highly aggressive non-Hodgkin lymphoma cancer originating in the lymph tissue (white blood cells) of the brain or spinal cord, and can also be found in the eyes.

CREDIBLE PARTY STILL IN NEGOTIATIONS

SUFFICIENT CASH FOR THE YEAR

NO UPDATE ON NON OWNED DEPOSITS

NEW CEO AFTER SALE OF ASSETS

NYUD – NO FINAL DECISION

COURT CASES – LOGIC – SETTLED. Q+M – CAN’T COMMENT ON ONGOING COURT CASE

NDA’S – VARIABLE AND NEW ONES SIGNED IN JUNE. 1 TO 3 YEAR TIME LINE

ANNUAL REPORT – MUCH TOUGER THIS YEAR – HENCE THE DELAY

OPTIONS – CHURAKOV ‘S CANCELLED

SALE PROCESS – BOD FOCUSSED ON THE SALE – MADE CLEAR MULTIPLE TIMES

JN LEAVING – EPC SPECIALIST SO NOT CURRENTLY NEEDED

NO ROYALTY PAID

DFS – LEGAL PROCEDURES NEED TO BE FOLLOWED BEFORE IT CAN BE PUBLISHED

RESOLUTIONS 6+7 – CRITICAL YEAR. HOPE TO FINALISE THE SALE SO OPTION NEEDS TO BE THERE IN CASE IT’S NEEDED

MT FLANKS – MKT WORK ONGOING

JORC – SUBJECT TO RUSSIAN SYSTEM AND WILL BE PUBLISHED WHEN DFS IS RELEASED

SUBSIDIARIES – MONEY CAPITALISED AS LOANS – PRE-WAR EXPENDITURE. NO INTERUPTIONS TO OPERTAIONS AT ALL IN RUSSIA

AM – VALUED MEMBER OF THE BOARD.

SINOSTEEL – NOT CONSIDERING AS SALE IS WHAT THEY WANT BUT IS STILL AN OPTION

PGM STOCKPILE – WILL BE SOLD

SALE CONFIDENCE – VERY HOPEFUL IT WILL BE COMPLETED THIS YEAR

GOOD RELATIONSHIP WITH RUSSIAN AUTHORITIES – NOT ENCOUNTERED ANY SERIOUS OBJECTIONS AND THEY’RE IMPRESSED WITH THE AUTHORITIES

CS – SIGNIFICANT SHAREHOLDER AND AT 70 YEARS OLD DESERVES A REST.

DIVIDEND – WILL BE PAID UPON SALE OF ASSETS

DRAG LINE PERFORMING VERY WELL AND IS CURRENTLY STOCK PILING ORE AFTER SOME MINOR GLITCHES EARLY ON

SIGNIFICANT SAVINGS BEING MADE USING ELECTRIC

EURASIA V2 – MOVING INTO H2 AND RENEWABLE ENERGY. STILL IN DEVELOPMENT

HANDS TIED WITH RESTRICTIONS REGARDING THE BUYER

LARGE SHAREHOLDERS NO BETTER INFORMED THAN PI’s

NEW CEO TO BE APPOINTED AFTER SALE IS COMPLETED

STILL NOT DIRECTLY AFFECTED BY SANCTIONS

BOD MUST PROTECT TRHE INTERESTS OF ALL SHAREHOLDERS